UBS Group’s Haemonetics HAE Stock Holding History

UBS Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-77,500	Closed	-$3.78M	–	10786
2025 Q3	$3.78M	Buy	+77,500	New	+$4.8M	﹤0.01%	4330

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's HAE Position: Q2 2026 in Review

UBS Group increased its Haemonetics (HAE) stake by 87% in Q2 2026, buying an estimated $29.3M and bringing the position to 983,378 shares worth $73.8M. The position accounts for 0.01% of the portfolio, ranked #1369.

UBS Group first reported a position in HAE in Q4 2014 and has held it in 47 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

UBS Group held 983,378 shares of Haemonetics worth $73.8M as of Q2 2026.
UBS Group bought 456,761 Haemonetics shares in Q2 2026, an estimated $29.3M.
Haemonetics made up 0.01% of UBS Group's portfolio in Q2 2026, its #1369 holding.
UBS Group first reported a position in Haemonetics in Q4 2014 and has held it in 47 quarters since.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.